Search Results
Apr 23, 2026, 09:00 ET AQST Investor Alert: AQUESTIVE THERAPEUTICS, INC. Securities Fraud Lawsuit - Investors With Losses May Seek to Lead the Class Action After Analyst Slashed Price Target: SueWallSt
(~$1/sh)" depending on the FDA's consideration of a Citizen PetitionOppenheimer compared the situation to prior FDA delays at SPRY (neffy) and ASND (Yorvipath), which resulted in 12 to 15 month approval delaysExecution Concerns on Wall StreetThe analyst commentary reveals
More news about: SueWallSt.com
Apr 15, 2026, 09:00 ET AQST Investor Alert: AQUESTIVE THERAPEUTICS, INC. Securities Fraud Lawsuit - Investors With Losses May Seek to Lead the Class Action After Analyst Slashed Price Target: Levi & Korsinsky
(~$1/sh)" depending on the FDA's consideration of a Citizen PetitionOppenheimer compared the situation to prior FDA delays at SPRY (neffy) and ASND (Yorvipath), which resulted in 12 to 15 month approval delaysExecution Concerns on Wall StreetThe analyst commentary reveals
More news about: Levi & Korsinsky, LLP
Apr 01, 2026, 09:00 ET AQST Investor Alert: AQUESTIVE THERAPEUTICS, INC. Securities Fraud Lawsuit - Investors With Losses May Seek to Lead the Class Action After Analyst Slashed Price Target: Levi & Korsinsky
(~$1/sh)" depending on the FDA's consideration of a Citizen PetitionOppenheimer compared the situation to prior FDA delays at SPRY (neffy) and ASND (Yorvipath), which resulted in 12 to 15 month approval delaysExecution Concerns on Wall StreetThe analyst commentary reveals
More news about: Levi & Korsinsky, LLP
Mar 25, 2026, 09:00 ET AQST Investor Alert: AQUESTIVE THERAPEUTICS, INC. Securities Fraud Lawsuit - Investors With Losses May Seek to Lead the Class Action After Analyst Slashed Price Target: Levi & Korsinsky
(~$1/sh)" depending on the FDA's consideration of a Citizen PetitionOppenheimer compared the situation to prior FDA delays at SPRY (neffy) and ASND (Yorvipath), which resulted in 12 to 15 month approval delaysExecution Concerns on Wall StreetThe analyst commentary reveals
More news about: Levi & Korsinsky, LLP
Mar 19, 2026, 09:00 ET AQST Investor Alert: AQUESTIVE THERAPEUTICS, INC. Securities Fraud Lawsuit - Investors With Losses May Seek to Lead the Class Action After Analyst Slashed Price Target: SueWallSt
(~$1/sh)" depending on the FDA's consideration of a Citizen PetitionOppenheimer compared the situation to prior FDA delays at SPRY (neffy) and ASND (Yorvipath), which resulted in 12 to 15 month approval delaysExecution Concerns on Wall StreetThe analyst commentary reveals
More news about: SueWallSt.com
Mar 18, 2026, 09:00 ET AQST Investor Alert: AQUESTIVE THERAPEUTICS, INC. Securities Fraud Lawsuit - Investors With Losses May Seek to Lead the Class Action After Analyst Slashed Price Target: Levi & Korsinsky
(~$1/sh)" depending on the FDA's consideration of a Citizen PetitionOppenheimer compared the situation to prior FDA delays at SPRY (neffy) and ASND (Yorvipath), which resulted in 12 to 15 month approval delaysExecution Concerns on Wall StreetThe analyst commentary reveals
More news about: Levi & Korsinsky, LLP
Mar 12, 2026, 09:00 ET AQST Lawsuit Alleges Analyst Slashed Price Target - AQUESTIVE THERAPEUTICS, INC. Investors Face Losses Following Analyst Slashed Price Target: SueWallSt
(~$1/sh)" depending on the FDA's consideration of a Citizen PetitionOppenheimer compared the situation to prior FDA delays at SPRY (neffy) and ASND (Yorvipath), which resulted in 12 to 15 month approval delaysExecution Concerns on Wall StreetThe analyst commentary reveals
More news about: SueWallSt.com